A detailed history of Sg Americas Securities, LLC transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Sg Americas Securities, LLC holds 9,530 shares of PCVX stock, worth $1.01 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,530
Previous 2,342 306.92%
Holding current value
$1.01 Million
Previous $177,000 515.25%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 03, 2024

BUY
$70.52 - $117.12 $506,897 - $841,858
7,188 Added 306.92%
9,530 $1.09 Million
Q2 2024

Jul 12, 2024

SELL
$60.06 - $78.77 $121,141 - $158,879
-2,017 Reduced 46.27%
2,342 $177,000
Q1 2024

May 06, 2024

BUY
$59.79 - $81.05 $260,624 - $353,296
4,359 New
4,359 $298,000
Q3 2023

Oct 13, 2023

BUY
$46.0 - $53.1 $1.29 Million - $1.49 Million
27,980 New
27,980 $1.43 Million
Q1 2023

Apr 28, 2023

BUY
$36.27 - $47.2 $843,495 - $1.1 Million
23,256 Added 84.97%
50,626 $1.9 Million
Q4 2022

Feb 02, 2023

BUY
$20.58 - $47.95 $248,976 - $580,099
12,098 Added 79.22%
27,370 $1.31 Million
Q3 2022

Oct 31, 2022

SELL
$21.69 - $28.53 $23,273 - $30,612
-1,073 Reduced 6.56%
15,272 $367,000
Q2 2022

Jul 29, 2022

BUY
$17.68 - $26.58 $288,979 - $434,450
16,345 New
16,345 $356,000
Q1 2022

Apr 29, 2022

SELL
$17.46 - $26.36 $177,306 - $267,685
-10,155 Closed
0 $0
Q4 2021

Feb 07, 2022

SELL
$19.32 - $26.45 $299,749 - $410,371
-15,515 Reduced 60.44%
10,155 $242,000
Q3 2021

Nov 01, 2021

BUY
$20.26 - $26.97 $520,074 - $692,319
25,670 New
25,670 $651,000
Q2 2021

Aug 12, 2021

SELL
$16.45 - $24.06 $110,445 - $161,538
-6,714 Closed
0 $0
Q1 2021

May 13, 2021

BUY
$18.66 - $29.16 $125,283 - $195,780
6,714 New
6,714 $133,000

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $6.3B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Sg Americas Securities, LLC Portfolio

Follow Sg Americas Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg Americas Securities, LLC with notifications on news.